ADPT Adaptive Biotechnologies Corp


$ 17.62 $ 0.76 (4.51 %)    

Wednesday, 05-Nov-2025 13:01:24 EST
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
$ 16.87
$ 17.59 x 103
$ 17.62 x 136
$ 16.68 - $ 17.74
$ 4.27 - $ 17.89
1,347,783
na
2.58B
$ 1.88
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cathie-wood-goes-all-in-on-peter-thiels-crypto-play-bullish-with-back-to-back-million-dollar-buys

Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Ot...

 btig-maintains-buy-on-adaptive-biotechnologies-raises-price-target-to-19

BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $14 t...

 piper-sandler-maintains-overweight-on-adaptive-biotechnologies-raises-price-target-to-20

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the pri...

 jp-morgan-maintains-overweight-on-adaptive-biotechnologies-raises-price-target-to-17

JP Morgan analyst Sebastian Sandler maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price ...

 guggenheim-initiates-coverage-on-adaptive-biotechnologies-with-buy-rating-announces-price-target-of-20

Guggenheim analyst Subbu Nambi initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy rating and announces ...

 jp-morgan-maintains-overweight-on-adaptive-biotechnologies-raises-price-target-to-14

JP Morgan analyst Rachel Vatnsdal maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price ta...

 td-cowen-maintains-buy-on-adaptive-biotechnologies-raises-price-target-to-15

TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $1...

 piper-sandler-maintains-overweight-on-adaptive-biotechnologies-raises-price-target-to-15

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the pri...

 adaptive-biotechnologies-q2-eps-017-beats-024-estimate-sales-58879m-beat-49400m-estimate

Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate...

 cathie-woods-ark-invest-loads-up-on-absci-offloads-crispr-therapeutics

Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation.

 adaptive-biotechnologies-integrates-adaptives-clonosseq-test-for-mrd-assessment-in-lymphoid-malignancies-into-oncoemr-flatirons-cloud-based-emr-platform

Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetic...

 craig-hallum-initiates-coverage-on-adaptive-biotechnologies-with-buy-rating-announces-price-target-of-15

Craig-Hallum analyst John Wilkin initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy rating and announce...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION